share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K:諾和諾德-股票回購計劃
美股SEC公告 ·  08/26 22:46
牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on August 26, 2024. The program, which began on February 6, 2024, aims to repurchase up to DKK 20 billion worth of shares over a 12-month period. As part of this initiative, a specific share repurchase plan was initiated on August 7, 2024, targeting the repurchase of B shares for an amount up to DKK 2.4 billion, to be completed by November 4, 2024. Since the last update on August 19, 2024, Novo Nordisk has acquired an additional 205,000 B shares at an average price of approximately DKK 914.16, amounting to a transaction value of DKK 187,386,081. This brings the total repurchased under the program to 540,187 B shares, with an accumulated transaction value of DKK 485,999,068. The company...Show More
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on August 26, 2024. The program, which began on February 6, 2024, aims to repurchase up to DKK 20 billion worth of shares over a 12-month period. As part of this initiative, a specific share repurchase plan was initiated on August 7, 2024, targeting the repurchase of B shares for an amount up to DKK 2.4 billion, to be completed by November 4, 2024. Since the last update on August 19, 2024, Novo Nordisk has acquired an additional 205,000 B shares at an average price of approximately DKK 914.16, amounting to a transaction value of DKK 187,386,081. This brings the total repurchased under the program to 540,187 B shares, with an accumulated transaction value of DKK 485,999,068. The company now holds 12,935,944 B shares as treasury shares, which is 0.3% of the share capital. The total number of A and B shares, including treasury shares, is 4,465,000,000. Since the start of the repurchase program, Novo Nordisk has bought back 11,607,313 B shares at an average price of DKK 879.94 per share, totaling DKK 10,213,705,118. Novo Nordisk is committed to defeating serious chronic diseases and employs approximately 69,000 people across 80 countries.
諾和諾德是一家領先全球的醫療保健公司,宣佈了其股票回購計劃的進展,時間是2024年8月26日。這個計劃始於2024年2月6日,旨在在12個月的時間內回購高達200億丹麥克朗的股票。作爲該計劃的一部分,於2024年8月7日啓動了一項特定的股票回購計劃,旨在以高達24億丹麥克朗的金額回購B類股票,並將於2024年11月4日完成回購。自2024年8月19日上次更新以來,諾和諾德已經以大約914.16丹麥克朗的平均價格收購了額外的2050000億股,交易總價值爲187,386,081丹麥克朗。這使得在該計劃下總計回購了5401870億股,累計交易總價值爲485,999,068丹麥克朗。該公司現持有12...展開全部
諾和諾德是一家領先全球的醫療保健公司,宣佈了其股票回購計劃的進展,時間是2024年8月26日。這個計劃始於2024年2月6日,旨在在12個月的時間內回購高達200億丹麥克朗的股票。作爲該計劃的一部分,於2024年8月7日啓動了一項特定的股票回購計劃,旨在以高達24億丹麥克朗的金額回購B類股票,並將於2024年11月4日完成回購。自2024年8月19日上次更新以來,諾和諾德已經以大約914.16丹麥克朗的平均價格收購了額外的2050000億股,交易總價值爲187,386,081丹麥克朗。這使得在該計劃下總計回購了5401870億股,累計交易總價值爲485,999,068丹麥克朗。該公司現持有129359440億股作爲庫藏股份,佔股本的0.3%。包括庫藏股在內的A類和B類股份總數爲4,465,000,000。自回購計劃開始以來,諾和諾德已經以每股平均879.94丹麥克朗的價格回購了116073130億股,總計金額爲10,213,705,118丹麥克朗。諾和諾德致力於戰勝嚴重慢性疾病,在80個國家僱傭了大約69,000人。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。